Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia

McLornan, Donal, Hay, Jodie, McLaughlin, Kirsty, Holohan, Caitriona, Burnett, Alan Kenneth, Hills, Robert Kerrin, Johnston, Patrick G., Mills, Ken Ian, McMullin, Mary Frances and Longley, Daniel B. 2013. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. British Journal of Haematology 160 (2) , pp. 188-198. 10.1111/bjh.12108

Full text not available from this repository.

Abstract

Chemoresistance is a major contributor to the aggressiveness of AML and is often due to insufficient apoptosis. The CFLAR gene is expressed as long and short splice forms encoding the anti-apoptotic proteins c-FLIPL and c-FLIPS (CFLARL and CFLARS, respectively) that play important roles in drug resistance. In univariate analyses of CFLAR mRNA expression in adult AML patients, those individuals with higher than median mRNA expression of the long splice form CFLAR(L) (but not the short splice form) had significantly lower 3 year overall survival (P = 0.04) compared to those with low expression. In cell line studies, simultaneous down-regulation of c-FLIPL and c-FLIPS proteins using siRNA induced apoptosis in U937 and NB-4 AML cells, but not K562 or OCI-AML3 cells. However, dual c-FLIPL/S downregulation sensitized all four cell lines to apoptosis induced by recombinant tumour necrosis factor-related apoptosis-inducing ligand (rTRAIL). Moreover, specific downregulation of c-FLIPL was found to recapitulate the phenotypic effects of dual c-FLIPL/S downregulation. The histone deacetylase (HDAC)1/2/3/6 inhibitor Vorinostat was found to potently down-regulate c-FLIPL expression by transcriptional and post-transcriptional mechanisms and to sensitize AML cells to rTRAIL. Further analyses using more selective HDAC inhibitors revealed that HDAC6 inhibition was not required for c-FLIPL down-regulation. These results suggest that c-FLIPL may have clinical relevance both as a prognostic biomarker and potential therapeutic target for HDAC inhibitors in AML although this requires further study.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Wiley-Blackwell
ISSN: 0007-1048
Last Modified: 15 Oct 2017 21:43
URI: http://orca-mwe.cf.ac.uk/id/eprint/49799

Citation Data

Cited 12 times in Google Scholar. View in Google Scholar

Cited 21 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item